Американское общество гирудотерапии

Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system

Structural biology study published in Journal of Molecular Biology (1999)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Геномика и протеомикаФармакология секрета слюнных желёзRester U et al. · Journal of molecular biology, 1999

Abstract

The serine proteinase plasmin is, together with tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), involved in the dissolution of blood clots in a fibrin-dependent manner. Moreover, plasmin plays a key role in a variety of other activation cascades such as the activation of metalloproteinases, and has also been implicated in wound healing, pathogen invasion, cancer invasion and metastasis. The leech-derived (Hirudo medicinalis) antistasin-type inhibitor bdellastasin represents a specific inhibitor of trypsin and plasmin and thus offers a unique opportunity to evaluate the concept of plasmin inhibition. The complexes formed between bdellastasin and bovine as well as porcine beta-trypsin have been crystallised in a monoclinic and a tetragonal crystal form, containing six molecules and one molecule per asymmetric unit, respectively. Both structures have been solved and refined to 3.3 A and 2.8 A resolution. Bdellastasin turns out to have an antistasin-like fold exhibiting a bis-domainal structure like the tissue kallikrein inhibitor hirustasin. The interaction between bdellastasin and trypsin is restricted to the C-terminal subdomain of bdellastasin, particularly to its primary binding loop, comprising residues Asp30-Glu38. The reactive site of bdellastasin differs from other antistasin-type inhibitors of trypsin-like proteinases, exhibiting a lysine residue instead of an arginine residue at P1. A model of the bdellastasin-microplasmin complex has been created based on the X-ray structures. Our modelling studies indicate that both trypsin and microplasmin recognise bdellastasin by interactions which are characteristic for canonically binding proteinase inhibitors. On the basis of our three-dimensional structures, and in comparison with the tissue-kallikrein-bound and free hirustasin and the antistasin structures, we postulate that the binding of the inhibitors toward trypsin and plasmin is accompanied by a switch of the primary binding loop segment P5-P3. Moreover, in the factor Xa inhibitor antistasin, the core of the molecule would prevent an equivalent rotation of the P3 residue, making exosite interactions of antistasin with factor Xa imperative. Furthermore, Arg32 of antistasin would clash with Arg175 of plasmin, thus impairing a favourable antistasin-plasmin interaction and explaining its specificity.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAmino Acid SequenceAnimalsBinding SitesCattleCrystallography, X-RayFactor Xa InhibitorsFibrinolysinHydrogen BondingInsect ProteinsInvertebrate HormonesLeechesModels, Molecular

Резюме

Crystal structure of bdellastasin–trypsin complex and modeling of bdellastasin–microplasmin system — first structural elucidation of an antistasin-type inhibitor from medicinal leech.

Почему это важно для гирудотерапии

This study determined the X-ray crystal structures of complexes between bdellastasin—an antistasin-type inhibitor from Hirudo medicinalis—and bovine and porcine beta-trypsin, refined to 3.3 Å and 2.8 Å resolution. Bdellastasin exhibits a bis-domainal antistasin-like fold; its interaction with trypsin is confined to the C-terminal subdomain's primary binding loop (residues Asp30–Glu38), with a reactive-site lysine at P1 rather than the arginine typical of related inhibitors. Modeling of the bdellastasin–microplasmin complex suggested canonical inhibitor binding, and structural comparisons explained why antistasin itself cannot inhibit plasmin. This work is relevant to ASH for understanding structure-function relationships of leech-derived protease inhibitors that target enzymes involved in coagulation and fibrinolysis. The study is purely structural/biochemical, with no in-vivo or clinical data.

Цитирование

Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.

Rester U et al. · Journal of molecular biology, 1999

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.